The European Medicines Agency (EMA) has launched a survey of pharmaceutical companies to assess their preparedness for the United Kingdom’s upcoming withdrawal from the European Union, as it hopes to identify any concerns about the continued supply of drugs during the Brexit transition.
The European Medicines Agency (EMA) has launched a survey of pharmaceutical companies to assess their preparedness for the United Kingdom’s upcoming withdrawal from the European Union, as it hopes to identify any concerns about the continued supply of drugs during the Brexit transition.
The EMA is sending its survey directly to companies based in the United Kingdom that hold central EU marketing authorizations for medicines—as well as companies that have their quality control, batch release, import manufacturing sites, or pharmacovigilance operations in the United Kingdom—about their Brexit-related plans. Specifically, the EMA hopes to gain insight into companies’ plans to submit transfers, notifications, or variations to their marketing authorizations.
The EMA says that it hopes that the survey will identify companies in which “…there is a need for concerted action” to ensure the uninterrupted supply of medicines after Brexit and that it can help the EMA and the European Commission plan how to best use their resources in the days ahead. The survey, says the EMA, may also “…serve to stimulate those companies who have not yet taken any action” in planning for Brexit to begin developing and implementing plans.
Concerns about the availability of medicines in the United Kingdom and European Union following Brexit have intensified in recent months; despite recent assurances from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency that there will be no sudden overhauls to UK regulatory frameworks after Brexit, the continued lack of progress on a UK—EU trade deal raises the specter of potential drug shortages.
In November, the European Federation of Pharmaceutical Industries and Associations (EFPIA), an industry group, released the results of its own survey of 43 pharmaceutical companies and 33 national associations, which found that 45% of respondents expect trade delays in the event of a “no deal” Brexit. Currently, 45 million patient-ready packages of medicines are supplied to the European Union from the United Kingdom each month (and the United Kingdom receives 37 million packages each month from the European Union). Any trade delays, according to the EFPIA, could create significant issues for medicine availability.
Pharmaceutical companies will have until February 9 to complete the newly launched EMA survey, and the agency will share its findings and recommendations with the European Commission.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.